shares of Momenta Pharmaceuticals Inc (MNTA) on
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The firm has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The firm’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The firm’s programs include M254, M281 (Anti-FcRn candidate) and M230.